Mesoblast (ASX:MSB) files positive clinical efficacy and safety data
02 Jan 2020 - Cellular medicinal provider, Mesoblast (ASX:MSB, NASDAQ:MESO) has lodged positive clinical efficacy and safety data with the US FDA for its lead product candidate, remestemcel-L.